Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Opioids Stories

2012-04-05 14:21:05

BEVERLY HILLS, Calif., April 5, 2012 /PRNewswire/ -- According to recent figures released by the Associated Press (AP), sales of oxycodone and hydrocodone increased dramatically between 2000 and 2010, and distribution of those painkillers has exploded in new parts of the country. Administrative director for WAISMANN METHOD® rapid detox treatment and registered addiction specialist, Clare Waismann, is cautioning Americans that this report provides evidence of a prescription painkiller...

2012-04-05 02:24:01

RALEIGH, N.C., April 5, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the Company will host a special event entitled "Treatment of Opioid Dependence: The Future Role of BEMA Buprenorphine/Naloxone" for investors and analysts on Wednesday, April 11, 2012 at 12:30 p.m. in New York City. This event will include insightful discussion from medical experts with extensive experience in the management of opioid dependence and treatment with...

2012-04-04 10:53:45

Study may enable more effective future treatments Researchers at the University of Montreal's Sainte-Justine Hospital have identified how neural cells like those in our bodies are able to build up resistance to opioid pain drugs within hours. Humans have known about the usefulness of opioids, which are often harvested from poppy plants, for centuries, but we have very little insight into how they lose their effectiveness in the hours, days and weeks following the first dose. "Our study...

2012-04-03 02:27:43

BOONTON, N.J., April 3, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics today announced Cara Therapeutics, Inc. completed its successful, first-in-man Phase 1 clinical trial using Unigene's oral formulation of Cara's peptide-based, peripherally-restricted kappa opioid receptor agonist, CR845. The trial was a single-center, double-blind, placebo-controlled study to evaluate the...

2012-04-03 02:27:02

SHELTON, Conn., April 3, 2012 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the successful completion of a first-in-man Phase I clinical trial of an oral formulation of its peptide-based, peripherally-restricted kappa opioid receptor agonist, CR845. The trial was a single-center, double-blind, placebo-controlled study to evaluate the pharmacokinetics (PK), safety and pharmacodynamics of CR845 in healthy volunteers. An intravenous formulation of CR845 is currently in clinical...

2012-04-02 02:28:38

SAN FRANCISCO, April 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate. NKTR-192 is designed to have a short-acting profile with rapid onset of pain relief for the treatment of acute pain. With a reduced rate of entry into the central nervous system (CNS) as compared to other...

2012-03-29 10:23:44

GLENVIEW, Ill., March 29, 2012 /PRNewswire-USNewswire/ -- Common practices for changing from one opioid to another, including use of published dose conversion ratios, may be contributing to the growing number of opioid-related fatalities, new research suggests. The results from a scientific literature review and a case study using this new model of opioid rotation are presented in the April issue of Pain Medicine, the official journal of the American Academy of Pain...

2012-03-28 23:00:33

Orange County Rehab 449Recovery speaks out against opiate addiction. San Clemente, CA (PRWEB) March 28, 2012 According to a story released on the New England Cable News website, the state of Oklahoma is now the number one state in prescription pain pill addiction and abuse. What is more disturbing according to data within the article is that the number of deaths as a result of drug overdoses is now averaging two a day; which is higher than the number of deaths caused annually by...

2012-03-27 05:16:05

(Ivanhoe Newswire) -- Opioid-based painkillers, such as morphine, have been the standard treatment of postoperative and chronic cancer pain for over 200 years. Two new studies show that opioid drugs may stimulate the spread and growth of tumors! "Epidemiologic findings suggest that the type of anesthesia we do for cancer surgery influences recurrence rate, and laboratory studies demonstrate that opioids influence tumor progression and metastasis. These studies have caused anesthesiologists...